Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study

Abstract Background Axitinib is used after failure of first line treatment for metastatic renal cell carcinoma (mRCC). A known side effect is the increase of haemoglobin level (HbL) during treatment with a suspected correlation with better outcome. Our objective was to examine whether HbL increase d...

Full description

Bibliographic Details
Main Authors: Alison C. Johnson, Margarida Matias, Helen Boyle, Bernard Escudier, Alicia Molinier, Brigitte Laguerre, Carole Helissey, Pierre-Emmanuel Brachet, Audrey Emmanuelle Dugué, Loic Mourey, Elodie Coquan, Florence Joly
Format: Article
Language:English
Published: BMC 2017-05-01
Series:BMC Cancer
Subjects:
Axitinib
Haemoglobin
High blood pressure
Polycythemia
Prognosis
Renal cell carcinoma
Online Access:http://link.springer.com/article/10.1186/s12885-017-3312-7

Internet

http://link.springer.com/article/10.1186/s12885-017-3312-7

Similar Items